Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, lif...
Leadership
Mark T. Iwicki
CEO & Director
Christopher H. Cabell FACC, M.D.
President, Head of Research & Development and Chief Medical Officer
David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A.
